Enliven Therapeutics lists 75,000-share resale via Jefferies

Enliven Therapeutics Inc. reported proposed resale transactions of common stock via Jefferies LLC for 75,000 shares with an aggregate value of $1,959,750 as of 02/18/2026.

Rhea-AI Filing Summary

Enliven Therapeutics Inc. reported proposed resale transactions of common stock via Jefferies LLC for 75,000 shares with an aggregate value of $1,959,750 as of 02/18/2026. The filing also lists multiple executed sales by Joseph Lyssikatos between 12/19/2025 and 02/06/2026, totaling reported proceeds of $4,234,611.77 across five transactions.

Insights

Securities Counsel

Form 144 discloses proposed and recent resale sales of Enliven common stock by a holder and by Jefferies as broker.

Enliven Therapeutics Inc. is shown with a planned brokered resale of 75,000 shares via Jefferies LLC valued at $1,959,750 with a trade date of 02/18/2026. The excerpt separately lists five prior sell transactions by Joseph Lyssikatos dated between 12/19/2025 and 02/06/2026, with per‑trade share counts and proceeds recorded in the table.

These entries are routine resale notices under securities rules. Timing and methods for the planned 75,000‑share resale are not further detailed in the excerpt; cash‑flow treatment for the planned sale is not specified in the provided excerpt. Subsequent SEC filings or broker disclosures may provide execution details.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Enliven Therapeutics' Form 144 show for 02/18/2026 (ELVN)?

The filing lists a proposed resale of 75,000 shares via Jefferies LLC with an aggregate value of $1,959,750 and a date of 02/18/2026. It indicates the shares are common stock to be sold on Nasdaq.

Who sold shares of ELVN in recent transactions listed in this excerpt?

Joseph Lyssikatos is shown as the seller in five transactions dated 12/19/2025 through 02/06/2026, reporting proceeds for each sale in the table and specific share counts per date.

How much proceeds are reported for Joseph Lyssikatos' sales in the excerpt?

The excerpt records aggregate proceeds of $4,234,611.77 across five listed transactions between 12/19/2025 and 02/06/2026, with individual proceeds shown per transaction in the table.

Does the Form 144 excerpt state how the 75,000 shares will be sold?

The excerpt identifies Jefferies LLC as the broker for the 75,000‑share resale but does not detail the plan of distribution or specific sale methods in the provided text; execution mechanics are not included in this excerpt.

Are the shares listed as founder shares or restricted in the filing?

The securities line shows the class as common 'Founder shares' with an original date of 09/01/2019, indicating the shares' origin as founder shares in the table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:25 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001967150
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 LOOKOUT ROAD BOULDER COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	Lyssikatos Joseph P
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	75000	1959750.00	59000000	02/18/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2019	Founder shares	Enliven Therapeutics			75000	09/01/2019	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	12/19/2025	5000	84206.00
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	01/08/2026	41302	993437.48
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	01/09/2026	91198	2482579.19
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	01/20/2026	20000	535099.00
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	02/06/2026	5000	145219.10

144: Remarks and Signature

Remarks	All sales are to be made pursuant to a previously signed/adopted 10b5-1 selling plan dated 11/15/2024, and all representations regarding material non-public information were made as of the adoption of the plan. The shares in this filing will be sold from The Lyssikatos Revocable Trust UAD 12/15/11.
Date of Notice	02/18/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/15/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Joseph Lyssikatos
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)